Literature DB >> 16637236

Invasive pneumococcal disease in Australia, 2004.

Paul W Roche1, Vicki L Krause, Mark Bartlett, David Coleman, Heather Cook, Craig Davis, James E Fielding, Ros Holland, Carolien Giele, Robin Gilmour, Riemke Kampen, Mitchell Brown, Lyn Gilbert, Geoff Hogg, Denise Murphy.   

Abstract

There were 2,375 cases of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System in Australia in 2004; a notification rate of 11.8 cases per 100,000 population. The rate varied between states and territories and by geographical region with the highest rates in the Northern Territory. Invasive pneumococcal disease was reported most frequently in children aged less than 5 years (55.4 cases per 100,000 population). Enhanced surveillance for IPD was carried out in all states and territories, in 2004, providing additional data on 2,023 (85%) cases. The overall rate of IPD in Indigenous Australians was 3.2 times the rate in non-Indigenous Australians. There were 154 deaths attributed to IPD resulting in an overall case fatality rate of 7.6 per cent. Rates of IPD in the Indigenous and non-Indigenous under 2-year-old population were similar in 2004 (91.5 and 93.6 cases per 100,000 population, respectively) following a targeted introduction of the 7-valent pneumococcal conjugate vaccine (7vPCV) in mid-2001 for Indigenous infants and children. Serotypes of isolates were identified from 80 per cent of all notified cases, with 72 per cent of isolates belonging to serotypes represented in the 7vPCV and 91 per cent in the 23-valent polysaccharide pneumococcal vaccine (23vPPV). Comparison of serotypes in the 7vPCV target population showed that the rate of IPD due to 7vPCV serotypes decreased by 74 per cent between 2001-02 and 2003-04. Of 216 isolates with reduced penicillin susceptibility, 83 per cent belonged to pneumococcal serotypes in the 7vPCV and 95 per cent in the 23vPPV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637236

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  6 in total

1.  Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.

Authors:  Xiaoping Xu; Lin Cai; Meng Xiao; Fanrong Kong; Shahin Oftadeh; Fei Zhou; Gwendolyn L Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

2.  Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance.

Authors:  H M Heffernan; D R Martin; R E Woodhouse; J Morgan; T K Blackmore
Journal:  Epidemiol Infect       Date:  2007-05-17       Impact factor: 2.451

3.  Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal people.

Authors:  Faye J Lim; Deborah Lehmann; Aoiffe McLoughlin; Catherine Harrison; Judith Willis; Carolien Giele; Anthony D Keil; Hannah C Moore
Journal:  Pneumonia (Nathan)       Date:  2014-12-01

4.  Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia.

Authors:  Rebecca J Rockett; Shahin Oftadeh; Nathan L Bachmann; Verlaine J Timms; Fanrong Kong; Gwendolyn L Gilbert; Vitali Sintchenko
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

5.  International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005.

Authors:  Michael G Bruce; Shelley L Deeks; Tammy Zulz; Dana Bruden; Christine Navarro; Marguerite Lovgren; Louise Jette; Karl Kristinsson; Gudrun Sigmundsdottir; Knud Brinkløv Jensen; Oistein Lovoll; J Pekka Nuorti; Elja Herva; Anders Nystedt; Anders Sjostedt; Anders Koch; Thomas W Hennessy; Alan J Parkinson
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

6.  Invasive bacterial diseases in northern Canada.

Authors:  Naushaba Degani; Christine Navarro; Shelley L Deeks; Marguerite Lovgren
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.